Literature DB >> 7092756

Women at altitude: cardiovascular responses to hypoxia.

B L Drinkwater, P O Kramár, J F Bedi, L J Folinsbee.   

Abstract

Six women mountaineers, 23-43 years of age, participated in a series of physiological tests prior to and during an expedition to Bhrigupanth (6798 m) in the Indian Himalayas. During a three-phase step test at sea level, carrying 0, 4.5, and 9.0 kg backpack weights, oxygen requirements represented 49.5-54.8% VO2 max. Recovery heart rates (HR) at 5-15 s were linearly related to exercise HR. At 4250 m, 5-15 s postexercise HR's were significantly higher than those at SL but returned to SL values after 3 min of rest. At 5000 m, HR's remained higher than those at SL throughout recovery. On returning to 4250 m after 3 weeks at higher altitudes, all postexercise HR's were back to SL levels. Supine HR's, higher at altitude than at SL during the ascent, returned to SL rates on return to 4250 m. Hemoglobin and hematocrit increased from 13.7 mg% and 42.4% at SL to 16.4 mg% and 52.6% after the climb. Resting blood pressure was significantly elevated at 4250 m during ascent but returned to SL values on the descent. During the cold pressor test, systolic pressure was unaffected by altitude; diastolic pressure increased less at altitude. While HR was unchanged at SL, a significant increase in HR was observed in postclimb CPT tests, even though perceived discomfort decreased.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7092756

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  2 in total

1.  Metabolic responses during initial days of altitude acclimatization in the eastern Himalayas.

Authors:  C K Basu; R K Gautam; R P Sharma; H Kumar; O S Tomar; R C Sawhney; W Selvamurthy
Journal:  Int J Biometeorol       Date:  1996-09       Impact factor: 3.787

2.  A change of heart: Mechanisms of cardiac adaptation to acute and chronic hypoxia.

Authors:  Alexandra M Williams; Benjamin D Levine; Mike Stembridge
Journal:  J Physiol       Date:  2022-08-28       Impact factor: 6.228

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.